EMA
Regulatory Science & Innovation Task Force
Christelle Monville obtained a PhD in Neurobiology in 2000. She is currently professor at Paris Saclay-Evry’s University and team leader at the Istem lab (France). The objectives of her group are (1) to develop pre-clinical studies required for the development...
En savoir +Dr Philippe Menasché is a cardiac surgeon at the Georges Pompidou European Hospital, Professor of Thoracic and Cardiovascular Surgery at the Paris-Cité University, and is in charge of an INSERM team dedicated to cell therapy for heart failure. After the...
En savoir +Dr. Frattini has over 20 years of experience in the field of hematological malignancies and joined Cellectis in August 2020 as Senior Vice President of Clinical Sciences where he has been responsible for Cellectis’ clinical leadership including the clinical development...
En savoir +Kajsa Löwenhielm loves to untie knots. Currently, she’s applying her problem-solving mindset to find efficient solutions to the talent gap in the biopharma industry. With a master’s degree in medical science, Kajsa embraces the challenge of making the complex clear...
En savoir +Fanny Delettre, PharmD, Ph.D ; Director of Biology, Therapy and Diagnosis Department in « Etablissement Français du sang » Bourgogne Franche Comté (EFS BFC) and researcher in UMR Right. During her Ph.D and her postdoc in immunology laboratory in Besançon,...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +Gavin joined MabDesign in 2019 and currently holds the position of Head of Scientific Affairs & Business Intelligence. In this role, Gavin oversees the strategic development and implementation of scientific initiatives including MabDesign’s Watchs editions, our multiple types of scientific...
En savoir +Melanie Rietenbach is a Global Product Manager for the Immunotherapy portfolio at Miltenyi Biotec. During the last 3 years, she has been working together with the R&D and Clinical Development Team in order to advance the development of tools to...
En savoir +Dr. Larry Brown currently serves as Chief Scientific Officer and Executive Vice President of Research at Noveome Biotherapeutics Inc. in Pittsburgh, PA, United States. He is leading the translation of the ST266 secretome therapeutic from proof of principle into the...
En savoir +Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...
En savoir +Dr. Ibon Garitaonandia is the Chief Scientific Officer at CellProthera, a French clinical stage biotechnology company developing stem cell based therapies for cardiovascular and ischemic indications. He is conducting a Phase 2 study in post-acute myocardial infarction (NCT02669810) and preclinical...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that led the development of a treatment that restored movement and sensory function to people with quadriplegic spinal cord injury, and a treatment for cancer that has saved...
En savoir +Dr Christopher Ball is a biotech client partner at IQVIA and a member of IQVIA’s cell and gene therapy commercialization team. He works strategically with biotech companies to help them get their therapies to more patients faster. Chris has over...
En savoir +Jean-Luc Schlick holds a PhD in Biochemistry and Molecular Biology from Sciences University of Franche-Comté (Besancon, Fr). He is a co-founder of RD-BIOTECH SAS founded in 2002 with Philippe Dulieu and Jean-François Musard. In 2002, he was head of the...
En savoir +European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...
En savoir +Mathieu Guerriaud is a Doctor of Pharmacy (PharmD) and a Doctor of Science (PhD). He is an associate professor in pharmaceutical law, teaching at the Faculty of Health Sciences while working as a researcher in a law laboratory: the CREDIMI....
En savoir +Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology. Dr. Lu graduated from Peking University Medical School, and had her residency training at the University of Nebraska Medical Center in USA. She completed her hematology and oncology fellowship at Stanford University Medical Center.
En savoir +Dr. Brandenberger is the Chief Technical Officer and oversees technical operations, including process and analytical development, supply chain, manufacturing, and quality for Nkarta’s engineered NK cell therapy candidates. He has more than 20 years of experience in process and analytical...
En savoir +Olivier graduated from ENSTBB engineering school in Bordeaux and earned a doctorate degree in cell and molecular biology from Paris Diderot University. He developed his expertise in preclinical research and translational science through more than 20 years of experience in...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +